drugset / Trial / NCT06989957

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

NCT06989957

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet

Timeline

Start
2025-09-17
Primary completion
2028-08
Completion
2029-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator MDMA Unknown
Comparator Psilocybin Other / unclassified